SCHEMBL4622472

SCHEMBL4622472

CCCN1Cc2ccccc2CC1C(=O)NC1C2CCC1CN(CCc1ccc3c(c1)OCC3)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.39
CHRM3 P20309 3/20 0.39
CHRM2 P08172 2/20 0.39
GHSR Q92847 2/20 0.39
DRD2 P14416 2/20 0.39
CHRM4 P08173 2/20 0.39
CHRM5 P08912 2/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRA2A P08913 1/20 0.39
KCNE1 P15382 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
HRH2 P25021 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649730 0.89 NAMPT (0.42) ADRA1AMMP8TSHR
SCHEMBL4650554 0.87 CHRM1 (0.41) CHRM1CHRM3CHRM2GHSRDRD2
SCHEMBL4925770 0.85 PTPN1 (0.44) CHRM1CHRM3CHRM2GHSRDRD2
SCHEMBL4648634 0.81 CHRM2 (0.40) CHRM1CHRM3CHRM2GHSRDRD2
SCHEMBL4649247 0.81 SIGMAR1 (0.44) DRD2TSHR
SCHEMBL4649542 0.78 NAMPT (0.41) HDAC8GLAMMP8MMP3TSHR
SCHEMBL4649174 0.69 TSHR (0.42) ADRA1AMMP8TSHR
SCHEMBL4649360 0.67 SIGMAR1 (0.48) DRD2TSHR
SCHEMBL4755411 0.66 CHRM2 (0.46) CHRM1CHRM3CHRM2GHSRDRD2
SCHEMBL4648949 0.66 PTPN1 (0.45) DRD2ADRA1AHDAC8TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US claimed
EP-1904495-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US disclosed
EP-1904495-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255188-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 CHRM1 4/4885CHRM3 1/4885CHRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.